Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Biblos-e Archivo. Repositorio Institucional de la UAM
Publicación Artículo científico (JournalArticle)

Compensatory activity of the PC-ME1 metabolic axis underlies differential sensitivity to mitochondrial complex I inhibition

  • Prado, Lucía del
  • Jaraíz Rodríguez, Myriam
  • Agro, Mauro
  • Zamora Dorta, Marcos Javier
  • Azpiazu, Natalia
  • Calleja Pardo, José Manuel
  • López Manzaneda, Mario
  • De Juan Sanz, Jaime
  • Fernández Rodrigo, Alba
  • Esteban, José Antonio
  • Girona, Mònica
  • Quintana, Albert
  • Balsa Martínez, Eduardo
Deficiencies in the electron transport chain (ETC) lead to mitochondrial diseases. While mutations are distributed across the organism, cell and tissue sensitivity to ETC disruption varies, and the molecular mechanisms underlying this variability remain poorly understood. Here we show that, upon ETC inhibition, a non-canonical tricarboxylic acid (TCA) cycle upregulates to maintain malate levels and concomitant production of NADPH. Our findings indicate that the adverse effects observed upon CI inhibition primarily stem from reduced NADPH levels, rather than ATP depletion. Furthermore, we find that Pyruvate carboxylase (PC) and ME1, the key mediators orchestrating this metabolic reprogramming, are selectively expressed in astrocytes compared to neurons and underlie their differential sensitivity to ETC inhibition. Augmenting ME1 levels in the brain alleviates neuroinflammation and corrects motor function and coordination in a preclinical mouse model of CI deficiency. These studies may explain why different brain cells vary in their sensitivity to ETC inhibition, which could impact mitochondrial disease management, This work was supported by grants to E.B. from the Spanish Government, Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (PID2019-110766GA-I00 and PID2022-137404OB-I00), European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation (ERC-2020-STG grant agreement n° 948478) and Fundación CRIS contra el cancer (PR_EX_2022-01). A.Q. was supported by grant PID2020-114977RB-I00 funded by MICIU/AEI /10.13039/501100011033. M.Z. was supported in part by an FPI-UAM PhD fellowship. We also thank Cristina Ugalde for the 143B ND2, CytB, Cox2 and WT cybrid cell lines
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Compensatory activity of the PC-ME1 metabolic axis underlies differential sensitivity to mitochondrial complex I inhibition

  • del Prado, Lucia
  • Jaraíz-Rodríguez, Myriam
  • Agro, Mauro
  • Zamora-Dorta, Marcos
  • Azpiazu, Natalia
  • Calleja, Manuel
  • Lopez-Manzaneda, Mario
  • de Juan-Sanz, Jaime|||0000-0002-1212-5623
  • Fernández-Rodrigo, Alba|||0000-0003-3834-0687
  • Esteban, José A.|||0000-0002-3759-3300
  • Girona, Mònica
  • Quintana Romero, Albert|||0000-0003-1674-7160
  • Balsa, Eduardo|||0000-0002-6836-7023
Deficiencies in the electron transport chain (ETC) lead to mitochondrial diseases. While mutations are distributed across the organism, cell and tissue sensitivity to ETC disruption varies, and the molecular mechanisms underlying this variability remain poorly understood. Here we show that, upon ETC inhibition, a non-canonical tricarboxylic acid (TCA) cycle upregulates to maintain malate levels and concomitant production of NADPH. Our findings indicate that the adverse effects observed upon CI inhibition primarily stem from reduced NADPH levels, rather than ATP depletion. Furthermore, we find that Pyruvate carboxylase (PC) and ME1, the key mediators orchestrating this metabolic reprogramming, are selectively expressed in astrocytes compared to neurons and underlie their differential sensitivity to ETC inhibition. Augmenting ME1 levels in the brain alleviates neuroinflammation and corrects motor function and coordination in a preclinical mouse model of CI deficiency. These studies may explain why different brain cells vary in their sensitivity to ETC inhibition, which could impact mitochondrial disease management. Mitochondrial diseases caused by ETC deficiencies affect cells differently. Here, the authors show that ETC inhibition activates a non-canonical TCA cycle to maintain NADPH levels, which explains the differential sensitivity observed between astrocytes and neurons.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Metabolic remodeling in astrocytes: Paving the path to brain tumor development

  • Jaraíz-Rodríguez, Myriam
  • del Prado, Lucia
  • Balsa, Eduardo
The brain is a highly metabolic organ, composed of multiple cell classes, that controls crucial functions of the body. Although neurons have traditionally been the main protagonist, astrocytes have gained significant attention over the last decade. In this regard, astrocytes are a type of glial cells that have recently emerged as critical regulators of central nervous system (CNS) function and play a significant role in maintaining brain energy metabolism. However, in certain scenarios, astrocyte behavior can go awry, which poses a significant threat to brain integrity and function. This is definitively the case for mutations that turn normal astrocytes and astrocytic precursors into gliomas, an aggressive type of brain tumor. In addition, healthy astrocytes can interact with tumor cells, becoming part of the tumor microenvironment and influencing disease progression. In this review, we discuss the recent evidence suggesting that disturbed metabolism in astrocytes can contribute to the development and progression of fatal human diseases such as cancer. Emphasis is placed on detailing the molecular bases and metabolic pathways of this disease and highlighting unique metabolic vulnerabilities that can potentially be exploited to develop successful therapeutic opportunities., This work was supported by grants to Dr. Balsa from the Spanish Government, Ministerio de Ciencia e Innovación (PID2019-110766GA-I00), European Union's Horizon 2020 research and innovation program (ERC-2020-STG-948478) and Fundación CRIS contra el cancer (PR_EX_2022-01)., Peer reviewed